Palvella Therapeutics, Inc.
PVLA
$50.13
-$3.29-6.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.63M | 8.97M | 5.94M | 4.84M | 3.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.55M | 20.21M | 14.10M | 11.15M | 7.64M |
| Operating Income | -26.55M | -20.21M | -14.10M | -11.15M | -7.64M |
| Income Before Tax | -28.38M | -23.08M | -17.43M | 7.06M | 11.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.38 | -23.08 | -17.43 | 7.06 | 11.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.38M | -23.08M | -17.43M | 7.06M | 11.00M |
| EBIT | -26.55M | -20.21M | -14.10M | -11.15M | -7.64M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.12 | -4.73 | -5.53 | -4.12 | -3.43 |
| Normalized Basic EPS | -2.00 | -2.93 | -3.37 | -3.33 | -2.96 |
| EPS Diluted | -3.12 | -4.73 | -5.53 | -4.12 | -3.43 |
| Normalized Diluted EPS | -2.00 | -2.93 | -3.37 | -3.33 | -2.96 |
| Average Basic Shares Outstanding | 38.80M | 29.52M | 20.27M | 14.98M | 14.98M |
| Average Diluted Shares Outstanding | 38.80M | 29.52M | 20.27M | 14.98M | 14.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |